J Fischer1, S van Koningsbruggen-Rietschel2, E Rietschel2, M J G T Vehreschild3, H Wisplinghoff1, M Krönke1, A Hamprecht4. 1. Institute for Medical Microbiology, Immunology and Hygiene, University Hospital of Cologne, Cologne, Germany. 2. CF Center, University Children's Hospital of Cologne, Cologne, Germany. 3. First Department of Internal Medicine, University of Cologne, Cologne, Germany. 4. Institute for Medical Microbiology, Immunology and Hygiene, University Hospital of Cologne, Cologne, Germany axel.hamprecht@uk-koeln.de.
Abstract
OBJECTIVES: Aspergillus spp. are the most frequently isolated filamentous fungi in the sputum of patients with cystic fibrosis (CF). Resistance to the azoles, the mainstay of current antifungal therapy, has been increasingly observed worldwide, but few data are available on the resistance of Aspergillus spp. in German CF patients. This study investigated the epidemiology of Aspergillus spp. and the molecular origin of azole resistance in a large German CF centre. METHODS: In total, 2677 respiratory samples from 221 CF patients collected between April 2010 and April 2013 were analysed; of these, 573 yielded Aspergillus spp., which were screened for azole resistance. Isolates with reduced susceptibility to itraconazole and/or voriconazole were tested according to the EUCAST reference procedure. Sequencing of cyp51A, the target of azole antifungals, was performed in all resistant isolates. RESULTS: Six isolates obtained from four patients were highly resistant to itraconazole (all identified as Aspergillus fumigatus sensu stricto); five of them were pan-azole resistant. The TR34/L98H mutation was the most frequent mutation identified in azole-resistant isolates (n = 4), followed by M220L and TR46/Y121F/T289A, a mutation previously reported from Belgium and the Netherlands only. Three of four patients harbouring azole-resistant A. fumigatus had not received any prior azole treatment. CONCLUSIONS: Resistance to azoles in Aspergillus spp. is still infrequent in German CF patients and is mainly caused by the TR34/L98H mutation. Worryingly, pan-azole-resistant TR46/Y121F/T289A has spread to Germany. Azole resistance has to be considered also in azole-naive CF patients and susceptibility testing of Aspergillus spp. isolates should be performed in all patients requiring treatment.
OBJECTIVES:Aspergillus spp. are the most frequently isolated filamentous fungi in the sputum of patients with cystic fibrosis (CF). Resistance to the azoles, the mainstay of current antifungal therapy, has been increasingly observed worldwide, but few data are available on the resistance of Aspergillus spp. in German CFpatients. This study investigated the epidemiology of Aspergillus spp. and the molecular origin of azole resistance in a large German CF centre. METHODS: In total, 2677 respiratory samples from 221 CFpatients collected between April 2010 and April 2013 were analysed; of these, 573 yielded Aspergillus spp., which were screened for azole resistance. Isolates with reduced susceptibility to itraconazole and/or voriconazole were tested according to the EUCAST reference procedure. Sequencing of cyp51A, the target of azole antifungals, was performed in all resistant isolates. RESULTS: Six isolates obtained from four patients were highly resistant to itraconazole (all identified as Aspergillus fumigatus sensu stricto); five of them were pan-azole resistant. The TR34/L98H mutation was the most frequent mutation identified in azole-resistant isolates (n = 4), followed by M220L and TR46/Y121F/T289A, a mutation previously reported from Belgium and the Netherlands only. Three of four patients harbouring azole-resistant A. fumigatus had not received any prior azole treatment. CONCLUSIONS: Resistance to azoles in Aspergillus spp. is still infrequent in German CFpatients and is mainly caused by the TR34/L98H mutation. Worryingly, pan-azole-resistant TR46/Y121F/T289A has spread to Germany. Azole resistance has to be considered also in azole-naive CFpatients and susceptibility testing of Aspergillus spp. isolates should be performed in all patients requiring treatment.
Authors: J J Vehreschild; C P Heussel; A H Groll; M J G T Vehreschild; G Silling; G Würthwein; M Brecht; O A Cornely Journal: Eur Radiol Date: 2017-01-12 Impact factor: 5.315
Authors: Ga-Lai M Chong; Wendy W J van de Sande; Gijs J H Dingemans; Giel R Gaajetaan; Alieke G Vonk; Marie-Pierre Hayette; Dennis W E van Tegelen; Guus F M Simons; Bart J A Rijnders Journal: J Clin Microbiol Date: 2015-01-07 Impact factor: 5.948
Authors: I Montesinos; M A Argudín; M Hites; F Ahajjam; M Dodémont; C Dagyaran; M Bakkali; I Etienne; F Jacobs; C Knoop; S Patteet; K Lagrou Journal: J Clin Microbiol Date: 2017-05-17 Impact factor: 5.948
Authors: Rose-Anne Lavergne; Florent Morio; Loïc Favennec; Stéphane Dominique; Jacques F Meis; Gilles Gargala; Paul E Verweij; Patrice Le Pape Journal: Antimicrob Agents Chemother Date: 2015-04-27 Impact factor: 5.191
Authors: Faezeh Mohammadi; Seyed Jamal Hashemi; Jan Zoll; Willem J G Melchers; Haleh Rafati; Parvin Dehghan; Sasan Rezaie; Ali Tolooe; Yalda Tamadon; Henrich A van der Lee; Paul E Verweij; Seyedmojtaba Seyedmousavi Journal: Antimicrob Agents Chemother Date: 2015-11-02 Impact factor: 5.191